This is an interview with Dr. Paul Wotton, who joined Cynata Therapeutics Board of Directors in June, 2016.  Dr. Wotton was previously President and CEO of Ocata Therapeutics, Inc. (NASDAQ: OCAT) joining the company in July 2014 and managing it through an all-cash take-over by Astellas Pharma valued at $379 million. [Read more…]
RoosterBio Commercializes Industry’s First cGMP Human MSC Banks For Widespread Manufacturing
RoosterBio Launches Only Commercially-Available Working Cell Banks (WCBs) for Large-Scale hMSC Production
Frederick, MD, USA. January 24, 2018 –Â RoosterBio Inc., a leading manufacturer of adult, allogeneic human mesenchymal stem/stromal cells (hMSCs) and paired bioprocess media systems, continues to deliver on its mission to de-bottleneck and accelerate the Regenerative Medicine Industry by launching the only commercially-available working cell banks (WCBs) for large scale hMSC production. [Read more…]
RegMed’s First Xeno-Free Human Mesenchymal Stem Cell (MSC) Cell Banks
RoosterBio has announced the launch of the Regenerative Medicine (RM) industry’s first xeno-free (XF) hMSC cell banks to advance and simplify stem cell biomanufacturing. By incorporating XF starting materials at early stages, RM scientists can perform more clinically relevant work, resulting in an expedited path towards clinical testing programs. Due of the importance of this announcement, I followed up with Dr. Priya Baraniak, Director of BD & Strategic Marketing at RoosterBio, to further explore details of the launch. [Read more…]
Cynata Therapeutics Initiates Patient Treatment in World 1st Clinical Trial
In breaking news released earlier this month, Cynata Therapeutics (ASX: CYP) announced a major world first. The company treated a patient with steroid resistant acute graft-versus-host disease (GvHD) as part of a phase 1 clinical study of its first mesenchymal stem cell (MSC) product, CYP-001 .
This is an important value catalyst for Cynata and also for the regenerative medicine industry, because it is the first time ever that a patient has been treated with an allogeneic induced pluripotent stem cell (iPSC)-derived therapeutic mesenchymal stem cell (MSC) product.
Patient Treatment Commences in Cynata’s World First Clinical Trial (CYP-001)
- First patient with steroid resistant acute graft-versus-host disease (GvHD) treated in Cynata’s phase 1 clinical study of its mesenchymal stem cell (MSC) product, CYP-001
- World first clinical trial using a MSC therapeutic product derived from an induced pluripotent stem cell sourced from a single blood donation from one donor
- Transition into active clinical trials cements Cynata’s world leading position in the development and commercialisation of second generation stem cell products
- Partnership with Fujifilm for the commercialisation of CYP-001; trial commencement accelerates this target
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- 8
- Next Page »